Dianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price rose 8.2% on Wednesday . The company traded as high as $21.75 and last traded at $21.49. Approximately 91,333 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 223,354 shares. The stock had previously closed at $19.86.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of analyst reports. Oppenheimer lifted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $46.83.

Dianthus Therapeutics Stock Performance

The company’s 50 day simple moving average is $22.53 and its two-hundred day simple moving average is $25.13. The stock has a market cap of $678.66 million, a price-to-earnings ratio of -9.18 and a beta of 1.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC grew its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after acquiring an additional 97,362 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after purchasing an additional 7,854 shares during the last quarter. Walleye Capital LLC bought a new stake in Dianthus Therapeutics in the third quarter worth $821,000. Finally, Braidwell LP increased its position in Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.